Global Ganja Report

The oddly named mapping website FloatingSheep.com has produced a map showing the differences in the retail price of cannabis in the United States, coast to coast. The map—apparently featured in the September issue of Wired magazine under the cheeky title "Infoporn: O Say, Can You THC?"—is based on information gleaned from consumer reports on the Price of Weed website.

A small Massachusetts-based company called Medicinal Genomics has announced the sequencing of the entire genomes of the species cannabis sativa and cannabis indica, opening the way for more research into the therapeutic effects of the plant—including its potential for treating cancer and inflammatory diseases. The company published the genetic code Aug. 18 on Amazon.com's EC2 cloud-computing system.

Superior Court Judge Paul Vortmann in California's Tulare County ruled Aug. 11 that a cannabis collective cannot operate on land zoned for agriculture, dismissing a property owner's arguments. "In this state, marijuana has never been classified as a crop or horticultural product," Vortmann wrote. Cannabis is a controlled substance, the ruling stated, adding that "the court finds as a matter of law that growing marijuana...is not an agricultural use of property."

The Oakland City Council on July 26 passed an ordinance that will double the number of medical marijuana dispensaries in the city, to eight from the current four—the Oakland Patient Center, the Purple Heart Patient Center, Coffeeshop Blue Sky, and the Harborside Health Center. The new ordinance was passed with an amendment that provides the city with access to all the dispensaries' financial information. And accompanying legislation imposes a $5,000 application fee and a $60,000 annual regulatory fee on each dispensary. The Council put off discussion of amending the city's cultivation ordinance, which would regulate large-scale cannabis farms, until the Public Safety Committee reconvenes in the fall. (Office of the City Clerk, City of Oakland, July 26; San Francisco Chronicle's Oakland Blog, July 13)

Entertainment Weekly's Inside TV blog reports July 20 that the Discovery Channel has announced a "docu-soap reality show" entitled Weed Wars, set in Oakland's Harborside Health Center, the USA's largest medicinal cannabis distributorship. Set to air this fall, Weed Wars will follow the day-to-day dealings of Steve DeAngelo, owner of the establishment, which serves some 80,000 clients. 

The average income of Mexican households fell by 12.3% between 2008 and 2010, the government's National Statistics and Geography Institute (INEGI) reported on July 15. The richest households generally lost the most in percentages, but poorer households suffered more because their income was already so low, according to the National Survey of Household Income and Expenditure, which the INEGI conducts every two years. The decline in income reflects a 6.1% contraction of the Mexican economy in 2009 in the midst of a world economic crisis that started in the US; the Mexican economy recovered partially in 2010 with a 5.4% expansion. (La Jornada, Mexico, July 16)

We have noted before that the cannabis industry has a huge carbon footprint—something of a dirty little secret for the legalization movement. David Downs in the July 13 issue of East Bay Express has a fascinating cover-story, "How Green Is Your Pot?" Traveling to backwoods Humboldt County, Downs finds: "A new collective is trying to sell sustainable, organically grown marijuana, but patients are hooked on indoor weed that wastes energy and pollutes the planet."

Less than two months after patient advocates filed a lawsuit compelling the federal government to answer a nine-year-old petition to reschedule medical marijuana, the Drug Enforcement Administration (DEA) on July 8 made official its denial of the petition in the Federal Register. The Coalition for Rescheduling Cannabis (CRC), which includes patient advocacy group Americans for Safe Access (ASA), filed the petition in 2002 seeking to reclassify cannabis from its current status as a dangerous drug with no medical value, but never heard from the federal government until it received the denial.